To promote further understanding between China and Japan as well as advance cultural exchange.
TOKYO, Sept 25, 2015 - (ACN Newswire) - Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its holding company in China, Eisai China Holdings Ltd., will sponsor lectures at the Japan Research Center of Fudan University, one of China's top academic institutes, in Shanghai. Through these sponsored lectures which are mainly for students of the university, Eisai aims to foster the development of individuals who have deep understanding of the society and culture of both China and Japan, and can contribute to the further advancement of friendly locations.
Established in 1905, Fudan University is a research based university that has produced many outstanding graduates not only within China but also internationally. In addition, the Japan Research Center located within the university conducts research on bilateral relations, particularly focusing on the Japanese economy, through economic, social and cultural exchange between Japan and China. Eisai helped support the establishment of the Japan Research Center in 1990.
The theme of these sponsored lectures is slated to be "Access & Innovation in the China Pharmaceutical Market." In cooperation with the Fudan University Japan Research Center, Eisai Group employees will give lectures, hold joint symposia involving Fudan University researchers and related government representatives, conduct other activities.
Furthermore, in recognition of Eisai's contributions from the establishment of the Japan Research Center until now, Fudan University conferred the honorary title of Emeritus Professor of the Fudan University Japan Research Center to Eisai Representative Corporate Officer and CEO Haruo Naito at a combined sponsorship and investiture ceremony held at the Japan Research Center on September 24, 2015.
Eisai's business in China has a history spanning almost 25 years. Eisai entered the China market in 1991 through a joint venture company, and established Eisai China Inc., a 100% wholly owned subsidiary which has a manufacturing site in Suzhou, Jiangsu province, in 1996. In addition, Eisai built a new parenteral facility in the same city in November 2014, and also determined plans for the construction of a new oral solid dose facility in February 2015 in order to further strengthen the supply chain in China. Meanwhile in December 2014, Eisai established Eisai China Holdings Ltd., a new autonomous management organization to control the China business.
Through these sponsored lectures, Eisai strives to foster individuals who are responsible for the future of the rapidly growing China pharmaceutical industry and address the diverse needs of patients and their families in China.
About Eisai
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Source: Eisai
Contact:
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2015 ACN Newswire . All rights reserved.
